Voluntary HIV screening among adults in France

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects information from adults about the ways they choose to get voluntary HIV screening. Participants 18 and older who agree to take part will report whether they used clinic testing, community services, self-tests, or other options. Data will be gathered at the Reims site and summarized to describe patterns by age, gender, and prior testing history. The goal is to map how the general population accesses voluntary HIV testing in France.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or older
* Male or female
* Regardless of sexual orientation
* Whether or not they have previously undergone voluntary HIV testing
* Agreeing to participate in the study.

Exclusion Criteria:

* Minors
* Refusing to participate in the study

Where it's running

• Ufr Medecine Urca
  Reims, France Recruiting

Study contacts

• Study coordinator: Gestonnairedu CURRS
• Email: currs@univ-reims.fr
• Phone: 0326918822

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cervical screening and care options for women living with HIV who test positive for high-risk HPV

  This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.

  Recruiting University of California, San Diego · Nairobi · NCT07925307

• Psilocybin Therapy for MeUD and HIV

  This study tests whether a single psilocybin dose, paired with motivational support therapy, can help people with HIV and moderate-to-severe methamphetamine use disorder stop using methamphetamine.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT07756736

• PrEP delivery led by HIV testing counselors in Kenyan clinics

  A counselor-led approach is being tested to see if it helps deliver PrEP in public health clinics for people in Kenya who may be at risk for HIV.

  Recruiting University of Washington · Kisumu · NCT07089966

• Monthly MK-8527 to prevent HIV-1 infection

  This study will test whether taking MK-8527 once a month prevents HIV-1 better than daily oral PrEP in HIV-negative, sexually active cisgender women.

  Recruiting at 21 sites Phase 3 Merck Sharp & Dohme LLC · Homabay County, Homa Bay County and 29 other locations · NCT07071623

• Adding fostemsavir to reduce inflammation in people with well-controlled HIV

  This trial will test whether adding fostemsavir to current HIV treatment lowers inflammation and heart disease risk for people with well-controlled HIV who have detectable sgp120.

  Recruiting Phase 2 Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Quebec · NCT07030920

• Quitting Matters: a smoking quit program for people living with HIV

  This 6-month program will test whether a tailored smartphone app plus nicotine patches and gum helps people living with HIV quit smoking better than a standard quit app.

  Recruiting Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT06883097

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.